Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans
Open Access
- 1 October 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 33 (8) , 439-446
Abstract
3,4-Methylenedioxymethamphetamine (MDMA), or ecstasy, is excreted as unchanged drug, 3,4-methylenedioxyamphetamine (MDA), and free and glucuronidated/sulfated 4-hydroxy-3-methoxymethamphetamine (HMMA), and 4-hydroxy-3-methoxyamphetamine (HMA) metabolites. The aim of this paper is to describe the pattern and timeframe of excretion of MDMA and its metabolites in urine. Placebo, 1.0 mg/kg, and 1.6 mg/kg oral MDMA doses were administered double-blind to healthy adult MDMA users on a monitored research unit. All urine was collected, aliquots were hydrolyzed, and analytes quantified by gas chromatography-mass spectrometry. Median Cmax, Tmax, ratios, first and last detection times, and detection rates were determined. Sixteen participants provided 916 urine specimens. After 1.6 mg/kg, median Cmax were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median Tmax of 13.9, 23.0, 9.2 and 23.3 h. In the first 24 h, 30.2–34.3% total urinary excretion occurred. HMMA last detection exceeded MDMA's by more than 33 h after both doses. Identification of HMMA as well as MDMA increased the ability to identify positive specimens but required hydrolysis. These MDMA, MDA, HMMA, and HMA pharmacokinetic data may be useful for interpreting workplace, drug treatment, criminal justice, and military urine drug tests. Measurement of urinary HMMA provides the longest detection of MDMA exposure yet is not included in routine monitoring procedures.Keywords
This publication has 28 references indexed in Scilit:
- Influences of Urinary pH on the Pharmacokinetics of Three Amphetamine‐Type Stimulants Using a New High‐Performance Liquid Chromatographic MethodJournal of Pharmaceutical Sciences, 2009
- Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine After Controlled Oral Administration to Young AdultsTherapeutic Drug Monitoring, 2008
- Sensitive Gas Chromatography-Mass Spectrometry Method for Simultaneous Measurement of MDEA, MDMA, and Metabolites HMA, MDA, and HMMA in Human UrineClinical Chemistry, 2006
- Prospective memory, everyday cognitive failure and central executive function in recreational users of EcstasyHuman Psychopharmacology: Clinical and Experimental, 2001
- An Exploration of the History and Controversies Surrounding MDMA and MDAJournal of Psychoactive Drugs, 2001
- Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humansBritish Journal of Clinical Pharmacology, 2000
- Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy VolunteersNeuropsychopharmacology, 1998
- The complications of 'ecstasy' (MDMA)1988
- Subjective Reports of the Effects of MDMA in a Clinical SettingJournal of Psychoactive Drugs, 1986
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: EntactogensJournal of Psychoactive Drugs, 1986